Home Eli Lilly

Eli Lilly

Looking to expand your partner network with leading companies like Eli Lilly? Consider joining Inpart's global network for free.

Stay informed about the latest news about Eli Lilly by subscribing to our newsletter.

What is Eli Lilly best known for?

Eli Lilly is a global pharmaceutical company specializing in the development and manufacturing of innovative medicines. It has a strong presence in various therapeutic areas, including neuroscience, diabetes, oncology, immunology, and cardiovascular diseases.

Where is Eli Lilly located?

Eli Lilly is headquartered in Indianapolis, Indiana, United States. The company operates globally with offices, research facilities, and manufacturing sites in various countries.

Got a news story for us related to Eli Lilly? Send it to us here.

Latest Posts

In Depth 26 Feb 2025

New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?

Find out how biotechs are fighting pain with new non-opioid pain medication, as they look to overcome the ongoing opioid crisis.

February 26, 2025 - 13 minutesmins - By Willow Shah-Neville

News and Trends 24 Feb 2025

Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?

This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues.

February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter

In Depth 27 Feb 2024

Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A?

Explore the strategic implications of Novo Nordisk’s $16.5B Catalent acquisition on drug supply and market competition.

February 27, 2024 - 7 minutesmins - By Jules Adam

In Depth 8 Feb 2024

Could we see a new dawn for hair loss treatments?

Discover the latest advances in hair loss treatments, from topical therapies to the the groundbreaking potential of JAK inhibitors.

February 8, 2024 - 8 minutesmins - By David Cox

Opinion 1 Nov 2023

Could this be the start of a new era for PI3K drugs?

There is hope that a rich biotech pipeline will produce a second generation of PI3K drugs, a type of kinase inhibitor, after issues with the first generation from the class had brought up concerns. Phosphoinositide 3-kinases (PI3K) drugs work by inhibiting a pathway that plays a role in cell metabolism, growth, proliferation and survival that […]

November 1, 2023 - 7 minutesmins - By External Contributor

In Depth 28 Sep 2023

Obesity drug success sparks biotech buying spree

The last few months have seen the obesity drug market soar, after new weight loss and diabetes drugs like Novo Nordisk’s Wegovy and Ozempic took the world by storm with their incredible efficacy at inducing weight loss. These new drugs belong to a class of medications called GLP-1 analogs (or incretin-based therapies), which work by […]

September 28, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 17 Jul 2023

Hope for Alzheimer’s patients after Lilly drug results

Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD). The data were shared at the 2023 Alzheimer’s Association International Conference (AAIC) as a featured symposium and simultaneously published in the Journal of […]

July 17, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Lilly boosts obesity portfolio with Versanis Bio acquisition

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis’ lead asset is bimagrumab, a monoclonal antibody that binds activin type II […]

July 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 14 Jul 2023

BioGeneration Ventures closes BGV Fund V at €150M

BioGeneration Ventures (BGV), an early-stage venture capital company in European biopharma, has closed its BGV V fund at €150 million ($167.9 million), its largest fund since launching its first fund in 2006. BGV V was oversubscribed, with demand from both existing and new investors, with existing investors Eli Lilly and Company, Novo Holdings and Bristol […]

July 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 22 Jun 2023

FDA approves type 2 diabetes drug for children 10 and older

The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company have announced. “As the burden of type 2 diabetes increases among young […]

June 22, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 May 2023

Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline

Eli Lilly and Company has announced positive results of the TRAILBLAZER-ALZ 2 phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease Rating Scale (iADRS). The primary endpoint of […]

May 3, 2023 - 8 minutesmins - By Jim Cornall

Best in Biotech 9 Mar 2023

5 advancements in kidney disease research over the past year

Prevalent in millions of people across the globe, kidney diseases manifest through various symptoms like blood and excess protein in urine, fluid retention causing swollen ankles, poor appetite and even the inability of the body to filter waste, resulting in acute kidney failure. To boost the research and development of treatments for kidney diseases, Kidney […]

March 9, 2023 - 7 minutesmins - By Roohi Mariam Peter

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Eli Lilly

What is Eli Lilly best known for?

Where is Eli Lilly located?

New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis?

Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?

Can the Novo Holdings-Catalent deal set a new standard for Pharma M&A?

Could we see a new dawn for hair loss treatments?

Could this be the start of a new era for PI3K drugs?

Obesity drug success sparks biotech buying spree

Hope for Alzheimer’s patients after Lilly drug results

Lilly boosts obesity portfolio with Versanis Bio acquisition

BioGeneration Ventures closes BGV Fund V at €150M

FDA approves type 2 diabetes drug for children 10 and older

Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline

5 advancements in kidney disease research over the past year

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!